Jeff Evans has been editor of Rheumatology News/MDedge Rheumatology and the EULAR Congress News since 2013. He started at Frontline Medical Communications in 2001 and was a reporter for 8 years before serving as editor of Clinical Neurology News and World Neurology, and briefly as editor of GI & Hepatology News. He graduated cum laude from Cornell University (New York) with a BA in biological sciences, concentrating in neurobiology and behavior.
News
British Society for Rheumatology cancels annual conference
The conference was scheduled to take place April 20-22 in Glasgow.
News
Hypertensive disorders of pregnancy in SLE contribute to later CV outcomes
Study confirms impact of such disorders, including preeclampsia, on incident hypertension and cardiovascular outcomes later in life.
News
TNFi treatment shows hint of slowing axial spondyloarthritis radiographic progression
But no effects on slowing spine or sacroiliac joint progression were seen in eight studies of NSAIDs and in one study of secukinumab.
News
What happens to clinically suspected arthralgia patients without RA?
The study is “the first to quantify the percentage of patients presenting with CSA that will have a resolution of symptoms over time.”
News
Two rheumatologists join MDedge Rheumatology editorial advisory board
Melissa S. Oliver, MD, and C. Kent Kwoh, MD, have joined the editorial advisory board.
News
Peripheral nervous system events have lasting impact on SLE patients
Findings from one of the largest-ever cohort studies on PNS manifestations in SLE patients may “provide a benchmark for the assessment of future...
News
Hadlima approved as fourth adalimumab biosimilar in U.S.
Hadlima gets seven of Humira’s indications.
News
Hadlima approved as fourth adalimumab biosimilar in U.S.
Hadlima gets seven of Humira’s indications.
Video
Efforts toward producing CNO/CRMO classification criteria show first results
MADRID – Cases are now being accepted for inclusion into a repository that will be used to develop and validate criteria.
Video
Bisphosphonates before denosumab may prevent postdenosumab BMD rebound effect
MADRID – Preliminary results suggest that using denosumab after bisphosphonates for rebound is effective and monitoring bone turnover markers at...
News
Mycophenolate, cyclophosphamide found equal as induction therapy in pediatric lupus nephritis
The study is the largest to date investigating induction treatments for proliferative lupus nephritis in JSLE.
News
Cimzia becomes first FDA-approved treatment for nonradiographic axial spondyloarthritis
Approval was based on the results of 52 weeks of double-blind therapy versus placebo.
News
Resistant hypertension hits SLE patients hard
Higher risk for resistant hypertension goes hand in hand with higher mortality.
News
Belimumab data out to 13 years show continued safety, efficacy
Continuation study describes longest treatment data available for belimumab.